TMCI

Company Overview — What Does TREACE MEDICAL CONCEPTS, INC. Do?

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida. TREACE MEDICAL CONCEPTS, INC. (TMCI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO John T. Treace and employs approximately 250 people. With a market capitalization of $91M, TMCI is one of the notable companies in the Healthcare sector.

TREACE MEDICAL CONCEPTS, INC. (TMCI) Stock Rating — Avoid (April 2026)

As of April 2026, TREACE MEDICAL CONCEPTS, INC. receives a Avoid rating with a composite score of 26.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.TMCI ranks #4,379 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TREACE MEDICAL CONCEPTS, INC. ranks #814 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TMCI Stock Price and 52-Week Range

TREACE MEDICAL CONCEPTS, INC. (TMCI) currently trades at $1.92. The stock gained $0.39 (25.5%) in the most recent trading session. The 52-week high for TMCI is $8.87, which means the stock is currently trading -78.4% from its annual peak. The 52-week low is $1.31, putting the stock 46.6% above its annual trough. Recent trading volume was 10.5M shares, indicating strong institutional interest and high liquidity.

Is TMCI Overvalued or Undervalued? — Valuation Analysis

TREACE MEDICAL CONCEPTS, INC. (TMCI) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.99x, versus the sector average of 2.75x. The price-to-sales ratio is 0.44x, compared to 1.66x for the average Healthcare stock.

At current multiples, TREACE MEDICAL CONCEPTS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

TREACE MEDICAL CONCEPTS, INC. Profitability — ROE, Margins, and Quality Score

TREACE MEDICAL CONCEPTS, INC. (TMCI) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -74.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -34.1% versus the sector average of -33.1%.

On a margin basis, TREACE MEDICAL CONCEPTS, INC. reports gross margins of 79.6%, compared to 71.5% for the sector. The operating margin is -32.6% (sector: -66.1%). Net profit margin stands at -33.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 13.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TMCI Debt, Balance Sheet, and Financial Health

TREACE MEDICAL CONCEPTS, INC. has a debt-to-equity ratio of 64.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.31x, indicating strong short-term liquidity. Total debt on the balance sheet is $56M. Cash and equivalents stand at $8M.

TMCI has a beta of 1.07, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for TREACE MEDICAL CONCEPTS, INC. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

TREACE MEDICAL CONCEPTS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, TREACE MEDICAL CONCEPTS, INC. reported revenue of $195M and earnings per share (EPS) of $-0.93. Net income for the quarter was $-65M. Gross margin was 79.6%. Operating income came in at $-63M.

In FY 2025, TREACE MEDICAL CONCEPTS, INC. reported revenue of $213M and earnings per share (EPS) of $-0.93. Net income for the quarter was $-59M. Gross margin was 79.8%. Revenue grew 1.6% year-over-year compared to FY 2024. Operating income came in at $-54M.

In Q3 2025, TREACE MEDICAL CONCEPTS, INC. reported revenue of $50M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-16M. Gross margin was 79.1%. Revenue grew 11.4% year-over-year compared to Q3 2024. Operating income came in at $-16M.

In Q2 2025, TREACE MEDICAL CONCEPTS, INC. reported revenue of $47M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-17M. Gross margin was 79.7%. Revenue grew 6.6% year-over-year compared to Q2 2024. Operating income came in at $-17M.

Over the past 8 quarters, TREACE MEDICAL CONCEPTS, INC. has demonstrated a growth trajectory, with revenue expanding from $44M to $195M. Investors analyzing TMCI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TMCI Dividend Yield and Income Analysis

TREACE MEDICAL CONCEPTS, INC. (TMCI) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TMCI Momentum and Technical Analysis Profile

TREACE MEDICAL CONCEPTS, INC. (TMCI) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

TMCI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, TREACE MEDICAL CONCEPTS, INC. (TMCI) ranks #814 out of 838 stocks based on the Blank Capital composite score. This places TMCI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TMCI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TMCI vs S&P 500 (SPY) comparison to assess how TREACE MEDICAL CONCEPTS, INC. stacks up against the broader market across all factor dimensions.

TMCI Next Earnings Date

No upcoming earnings date has been announced for TREACE MEDICAL CONCEPTS, INC. (TMCI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TMCI? — Investment Thesis Summary

The quantitative profile for TREACE MEDICAL CONCEPTS, INC. suggests caution. The quality score of 35/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 32/100) increases portfolio risk.

In summary, TREACE MEDICAL CONCEPTS, INC. (TMCI) earns a Avoid rating with a composite score of 26.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TMCI stock.

Related Resources for TMCI Investors

Explore more research and tools: TMCI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TMCI head-to-head with peers: TMCI vs AZN, TMCI vs SLGL, TMCI vs VMD.